Develops drugs for rare diseases like hereditary angioedema.
Jun 2026Revenue $941M/yrExpenses $1.25B/yr
No trend
Figures by year
When will Biocryst Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $941M and expenses $1.25B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $875M | $534M | $341M |
| Dec 2024 | $451M | $453M | −$2.54M |
| Dec 2023 | $331M | $435M | −$104M |
| Dec 2022 | $271M | $419M | −$148M |
| Dec 2021 | $157M | $335M | −$178M |
| Dec 2020 | $17.8M | $193M | −$175M |
| Dec 2019 | $48.8M | $148M | −$99.5M |
| Dec 2018 | $20.7M | $115M | −$94.2M |
| Dec 2017 | $25.2M | $82.6M | −$57.4M |
| Dec 2016 | $26.4M | $75.0M | −$48.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.